14.3% Below Target

Cardinal Health, Inc. (CAH) has a consensus 12-month price target of $253.38, implying 14.3% upside from $221.77. The 33 analysts covering CAH see moderate appreciation potential.

CAH has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $253.38 implies 14.3% upside from current levels.

CAH trades at a forward P/E of 20.5953x, representing a moderate valuation. With analysts targeting $253.38 (14.3% implied move), the stock appears reasonably valued with upside.

The most bullish Wall Street analyst has a price target of $275 for CAH, while the most conservative target is $235. The consensus of $253.38 represents the median expectation. Our quantitative valuation model projects a bull case target of $372 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CAH is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 15 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CAH stock forecast based on 33 Wall Street analysts shows a consensus price target of $253.38, with estimates ranging from $235 (bear case) to $275 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $282, with bear/bull scenarios of $178/$372.

Our quantitative valuation model calculates CAH's fair value at $282 (base case), with a bear case of $178 and bull case of $372. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.

CAH trades at a forward P/E ratio of 20.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are optimistic on CAH, with a "Buy" consensus rating and $253.38 price target (14.3% upside). 18 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CAH analyst price targets range from $235 to $275, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $253.38 consensus represents the middle ground. Our model's $178-$372 range provides an independent fundamental perspective.